Literature DB >> 14532154

Alpha 4 integrin blockade in inflammatory bowel disease.

S Ghosh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14532154      PMCID： PMC1766747          DOI： 10.1136/ard.62.suppl_2.ii70

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  8 in total

1.  Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.

Authors:  S Schreiber; S Nikolaus; H Malchow; W Kruis; H Lochs; A Raedler; E G Hahn; T Krummenerl; G Steinmann
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

2.  A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.

Authors:  B R Yacyshyn; M B Bowen-Yacyshyn; L Jewell; J A Tami; C F Bennett; D L Kisner; W R Shanahan
Journal:  Gastroenterology       Date:  1998-06       Impact factor: 22.682

3.  Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7.

Authors:  P E Hesterberg; D Winsor-Hines; M J Briskin; D Soler-Ferran; C Merrill; C R Mackay; W Newman; D J Ringler
Journal:  Gastroenterology       Date:  1996-11       Impact factor: 22.682

4.  A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

Authors:  F H Gordon; C W Lai; M I Hamilton; M C Allison; E D Srivastava; M G Fouweather; S Donoghue; C Greenlees; J Subhani; P L Amlot; R E Pounder
Journal:  Gastroenterology       Date:  2001-08       Impact factor: 22.682

5.  A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin.

Authors:  F H Gordon; M I Hamilton; S Donoghue; C Greenlees; T Palmer; D Rowley-Jones; A P Dhillon; P L Amlot; R E Pounder
Journal:  Aliment Pharmacol Ther       Date:  2002-04       Impact factor: 8.171

6.  Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody.

Authors:  D K Podolsky; R Lobb; N King; C D Benjamin; B Pepinsky; P Sehgal; M deBeaumont
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

7.  Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease.

Authors:  D G Binion; G A West; E E Volk; J A Drazba; N P Ziats; R E Petras; C Fiocchi
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

8.  Natalizumab for active Crohn's disease.

Authors:  Subrata Ghosh; Eran Goldin; Fiona H Gordon; Helmut A Malchow; Jørgen Rask-Madsen; Paul Rutgeerts; Petr Vyhnálek; Zdena Zádorová; Tanya Palmer; Stephen Donoghue
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245
  8 in total
  3 in total

1.  Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine.

Authors:  Elisha Waldman; Sydney X Lu; Vanessa M Hubbard; Adam A Kochman; Jeffrey M Eng; Theis H Terwey; Stephanie J Muriglan; Theo D Kim; Glenn Heller; George F Murphy; Chen Liu; Onder Alpdogan; Marcel R M van den Brink
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

Review 2.  Optimizing the safety of biologic therapy for IBD.

Authors:  Shanika de Silva; Shane Devlin; Remo Panaccione
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

3.  Natalizumab for induction of remission in Crohn's disease.

Authors:  Seana Ml Nelson; Tran M Nguyen; John Wd McDonald; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2018-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.